|
March 2003 (v03-n03) |
|
- Main Story - pgs. 1-12 Adolor Corporation
- Macro Market Commentary - pgs. 13-14
- Publication Changes - pg. 15
- Biotech Monthly Coverage Update - pg. 16-18
- NIBM Model Portfolio - pg. 19
- (Full outline below...)
|
 |
|
| It's probably not the sexiest
target in the world, but constipation related to the use of painkillers or from abdominal
surgery is a serious problem. It extends hospital stays and is a real burden for those who
use opiods (morphine, codeine) for relief from chronic pain. It's also a lucrative condition. If Adolor and partner Glaxo are
able to take alvimopan to market in both target indications, the companies will have a
solid blockbuster on their hands. |
 |
|
| The following is an outline of this issue of
the NIBM Newsletter. |
Subscriber direct access |
|
| |
|
|
- Main Story - Adolor
- Introduction
- Table: Basic Facts
- Disclosures
- Investment Case
- Constipation science
- How pain works
- Table: Pain Types
- Side effects
- The blood/brain barrier
- Opioid bowl dysfunction (OBD)
- Post-Operative Ileus (POI)
- Is it OBD or POI?
- Chart: Illustration of OBD vs. POI
- Alvimopan
- Clinical progress
- OBD trials
- Table: Alvimopan Phase II and Phase III comparison
- POI Trials
- Table: Alvimopan Phase II POI
- Table: Alvimopan Phase III trial comparison
- Acute OBD
- POI trial timelines
- Market Size
- Glaxo Deal
Alvimopan + Opioid
- Kappa-opioid analgesics
- ADL 10-0101
- ADL 10-0116
PNS-restricted mu opioids
Table: Adolor Milestones
What Can Go Wrong
Macro Market Commentary
Publication changes
- Biotech Monthly Coverage Updates
- Dendreon
- Genta
- Titan Pharmaceuticals
- PAREXEL
- Alteon
- Ęterna
- Targeted Genetics
- Indevus
- Esperion
|
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
